文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌单次19 Gy高剂量率近距离放疗局部失败剂量学分析

Dosimetry of local failure with single dose 19 Gy high-dose-rate brachytherapy for prostate cancer.
PubMed 文献 · Radiother Oncol · 2021-01-23

该回顾性研究分析2013–2018年接受单次19 Gy高剂量率近距离放疗(HDR BT)的前列腺癌患者,中位随访36个月,10.6%出现生化复发,其中多数局部复发位于原发病灶部位;匹配分析未发现复发与HDR BT剂量学参数相关,作者建议中高危患者至少采用两次分割。

要点

  • 单次19 Gy HDR BT后生化复发率10.6%,局部复发多位于原DIL部位。
  • 匹配分析中CTV、PTV、DIL及OAR剂量学参数在复发组与对照组间无显著差异。
  • Cox回归未发现临床或剂量学参数可预测bPFS、LR-PFS或DIL-PFS。

核心结论

  • 在本队列接受19 Gy单次HDR BT的患者中,未发现生化复发与HDR BT剂量学之间存在关联。
  • 大部分复发发生于原发病灶部位,中高危前列腺癌HDR BT应至少采用两次分割。

研究设计与样本

  • 回顾性分析2013–2018年接受19 Gy单次HDR BT单药治疗的180例前列腺癌患者。
  • 采用配对分析,每例生化复发患者匹配一例对照,匹配因素包括治疗前CTV大小、Gleason评分、T分期、风险分组及可识别DIL的存在。
  • 复发灶在诊断性T2加权MRI及胆碱PET上勾画并配准至原HDR BT计划CT,评估CTV、PTV、DIL及OAR剂量学参数。
  • 统计方法包括Wilcoxon符号秩检验及Cox回归分析。

主要发现

  • 中位随访36个月,19例(10.6%)出现生化复发。
  • 19例生化失败患者中13例发生局部复发,其中7例复发位于DIL部位。
  • Cox回归分析中,所考察的协变量均未发现对bPFS、LC-PFS及DIL-PFS有统计学显著预测价值。

关键数值与推荐

  • 单次分割剂量为19 Gy HDR BT。
  • 生化复发定义为19例(10.6%),局部复发13例,DIL部位复发7例。
  • 剂量学参数比较的显著性阈值p > 0.05(无显著差异)。

临床怎么用

  • 对于中高危前列腺癌患者,HDR BT应至少采用两次分割而非单次19 Gy。
  • 单次19 Gy方案下复发多位于原病灶,提示需关注DIL的覆盖与剂量分布。
  • 本研究中剂量学参数未能预测复发,计划评估不能仅依赖传统剂量学指标。

局限性

  • 回顾性研究设计。
  • 中位随访时间36个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/OBJECTIVE: Long-term follow up of single dose high-dose rate brachytherapy (HDR BT) for localised prostate cancer has revealed higher than expected rates of biochemical and local failure. This study aimed (i) to investigate the pattern of relapse within the prostate with reference to the initial site of disease in those patients; and (ii) to examine if there were any relationships between the HDR BT dosimetric parameters to these areas of recurrence. MATERIALS/METHODS: A retrospective review of treatment records of patients who received 19 Gy single fraction of HDR BT was carried out. A matched pair analysis used one control for each biochemical recurrence case matched with pre-treatment Clinical target volume (CTV) size, Gleason score, T stage, risk category and presence of an identifiable dominant intraprostatic nodule (DIL) for each biochemical recurrence case identified. For all datasets, the pre HDR BT DILs were delineated on the diagnostic pre-treatment T2-weighted MRI and planning CT images. For patients with local recurrence post HDR BT, the recurrent nodules were contoured on the diagnostic T2-weighted MRI and choline PET which were registered to the original HDR BT planning CT. Dosimetric parameters of CTV, planning target volume (PTV), DIL and organs at risk (OARs) were evaluated. Wilcoxon signed-rank test was performed to investigate if there were any significant differences in dosimetric parameters between cases and controls. Cox regression analysis was performed to explore if there were any clinical and dosimetric parameters predicting for biochemical progression free survival (bPFS), local recurrence free survival (LR-PFS) and DIL recurrence free survival (DIL-PFS). RESULTS: Between 2013 and 2018, 180 patients received 19 Gy HDR-BT monotherapy. With a median follow up of 36 months, 19 (10.6%) patients developed biochemical recurrence. Of the 19 patients with biochemical failure, 13 had a local recurrence, including 7 who occurred at the site of DIL. Thirty-eight intermediate/high risk patients were included in the matched pair analysis. No statistically significant differences were found in all CTV, PTV, DIL and OAR dosimetric parameters between cases and controls (p > 0.05). For the Cox regression analysis, none of the covariates investigated were found to be statistically significant factors to predict for bPFS, LC-PFS and DIL-PFS. CONCLUSION: No associations between biochemical recurrences and HDR BT dosimetry were identified in our cohort of patients receiving 19 Gy single fraction HDR BT. A large proportion of recurrences occurred at the site of original disease. HDR BT for intermediate/high risk prostate cancer should be undertaken using a minimum of two fractions.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Armstrong S, Tsang Y, Lowe G, et al. Dosimetry of local failure with single dose 19 Gy high-dose-rate brachytherapy for prostate cancer. Radiother Oncol. 2021. PMID: 33493500. doi:10.1016/j.radonc.2021.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。